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Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality
Based on surrogate markers of benefit, single-arm studies projected that lung cancer screening with computed tomography (CT) would reduce lung cancer mortality by 80%.
1 Yet subsequent randomized clinical trials produced findings ranging from no reduction to a 20% reduction. 2 We formally evaluated the seemingly misleading surrogates.
Methods | In each of the 33 separate sites of the randomized National Lung Screening Trial (NLST) 3 we assessed the relation between the magnitude of the actual benefit observed and 3 separate surrogates of benefit: 1. The proportion of stage 1 lung cancers diagnosed in the CT arm out of all lung cancer diagnoses, with a logarithmic transformation applied to improve adherence to mathematical assumptions. 2. Lung cancer-specific survival at 4 years among participants in the CT arm found to have stage 1 lung cancer (median follow-up was 53 months), with censoring was either for death from another cause or end of follow-up. 3. The ratio of the proportion of stage 1 lung cancers diagnosed between the study arms, with a logarithmic transformation applied.
4
Using a weighted Pearson correlation coefficient (weights were the total number of lung cancer diagnoses at the study unless otherwise noted), we evaluated the relation between each surrogate and the difference in rates of death from lung cancer in the CT arm vs the chest x-ray (CXR) arm. Two sided P values <.05 were considered statistically significant. Statistical analyses were performed using R statistical software (version 3.2.2, R Foundation) including the weights and car packages. The NLST is a public use file exempt from institutional review board approval or written informed consent.
Results | We analyzed data from 26 722 CT patients and 26 730 CXR patients, for a total of 53 452 patients. The mean (SD) age was 61 (5) years, with 31 530 (59%) men. The site-level magnitude of lung cancer mortality reduction was not associated with either the proportion of stage 1 lung cancers diagnosed in the CT arm (Pearson correlation, -0.08; 95% CI, -0.41 to 0.27; P = .65) or 4-year lung cancer-specific survival rate of participants in the CT arm diagnosed with stage 1 lung cancer (Pearson correlation, -0.28; 95% CI, -0.58 to 0.09; P = .13) ( Figure) . The difference in the proportion diagnosed with stage 1 lung cancer between study arms (means, CT 54% and CXR 34%; P < .001) was neither correlated with the difference in lung cancer mortality (Pearson correlation, -0.28; 95% CI, -0.57 to 0.07; P = .12) nor did it attenuate the main effect of the intervention in a regression analysis (P < .001) (Table) .
Discussion | Good surrogate markers of important endpoints can make studies more efficient; poor ones can be misleading. Early single-arm studies of CT screening that used surrogate markers estimated that CT screening would reduce lung cancer death by 80% or more; later randomized clinical trials estimated a benefit ranging from 0% to 20%. The recently published randomized Danish Lung Cancer Screening Trial (DLCST) 5 illustrates the problem clearly. Although there was clear evidence that CT screening was associated with a far higher rate of stage 1 lung cancer diagnoses than the control group (50 vs 8, P < .001), lung cancer deaths in the 2 arms were essentially equal (39 screening vs 38 usual care).
5
Some researchers have considered improvements in surrogate markers of screening benefits to be synonymous with evidence that CT screening is improving patient outcomes. 6 Yet our analysis suggests that drawing such a conclusion is inappropriate. We conclude that these surrogate markers must not be used to evaluate the benefits of CT screening. We base this on not only our analyses, but the observation that these surrogate markers have been poor at predicting CT screening benefits both between and within studies, and the basic epidemiologic biases associated with screening, such as length biased sampling, are known to inflate the surrogates without improving outcome. A quest for more reliable predictive markers of CT screening impact on patient outcomes is warranted. Lack of statistical relation between study site-level effect of computed tomography (CT) screening on lung cancer mortality compared with control arm compared with 2 surrogate markers of that benefit-proportion of stage 1 lung cancers in the CT arm of the study (solid regression line, P = .65); 4-year lung cancer specific survival among those with stage 1 lung cancer in the CT arm (dashed regression line, P = .13). In each case the slope of the regression lines is more consistent with a negative than a positive correlation between these surrogates and the impact of CT screening on lung cancer mortality. The circles represent the site-level data points for the proportions of stage 1 lung cancers, the triangles represent the site-level data points for the 4-year survival rates in the CT arm. 
US Public Perceptions About Cancer Care Provided by Smaller Hospitals Associated With Large Hospitals Recognized for Specializing in Cancer Care
Over the past 5 years, smaller hospitals have developed formal relationships with larger hospitals at a historic rate, with more than 100 new mergers, acquisitions, and affiliations being filed each year in the United States. 1,2 Applying the brand of a larger hospital to smaller, affiliated hospitals has become commonplace. 3 This brand sharing has the potential to influence patient decisions about where to pursue care, particularly for complex conditions such as cancer. 4 However, the extent to which patients perceive the care at the smaller hospitals to be affected by affiliation is unclear. In an effort to understand patient expectations associated with brand sharing for complex cancer care at smaller hospitals, we surveyed a nationally representative sample in the United States.
Methods | An internet KnowledgePanel survey (GfK Group) was distributed across a nationally representative adult sample in November 2017. 5 Respondents were asked to consider a smaller hospital developing a relationship (affiliation) with a larger hospital recognized for specializing in cancer care, and questioned regarding the impact of the affiliation on the smaller hospital (questionnaire available on request). To account for variable response rates across sociodemographic strata, results were weighted (using age, sex, race, region, metropolitan area, income, education, and home ownership) to mirror the US population and are reported with 95% confidence intervals (CIs). The study was approved by the Yale University Human Investigations Committee, which provided a waiver of written informed consent. Respondents were not compensated directly, but were periodically entered into raffles run by GfK group to encourage participation. Overall, 943 (94%) respondents felt that cancer care at a smaller hospital would improve after affiliating with a larger hospital specializing in cancer. A total of 131 (14%) respondents believed improvement would happen right away, 392 (39%) within 6 months, and 738 (73%) within a year. After affiliation, respondents expected physicians at the larger hospital to be involved considerably in the care of patients at the smaller hospital (Table 1) . Most respondents (594 [60%]) believed physicians from the larger hospital were "often" or "always" involved in at least 1 of 5 potential areas of care integration. Specifically, 922 (92%) respondents expected surgeons from the larger hospital to operate at the smaller hospital, including 308 (32%) who felt this would take place "often" or "always" (Table 1) .
Regarding the impact of affiliation on patient choice, 785 (77%) respondents indicated they would choose to have complex cancer surgery at a smaller hospital that was affiliated with a larger hospital over a smaller hospital without an affiliation. 
